Modus Therapeutics and Imperial College London Sign Clinical Collaboration Targeting Severe Malaria
Project is supported by Wellcome STOCKHOLM, SWEDEN – 11 June 2021: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with high unmet medical needs, announces that it has entered a clinical research collaboration with a team led by Professor Kathryn Maitland from Imperial College London, UK. The project aims at researching the effect of the Company’s proprietary drug sevuparin in patients with severe malaria. Modus is currently developing sevuparin in sepsis/septic shock, and other conditions with systemic inflammation, with severe malaria